Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cinnarizine→

Cinnarizine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
298-57-7
Molecular formula
C26H28N2
Molecular weight
368.5139 g/mol
Drug class
Piperazine derivativeantihistamine with calcium-channel-blocking activityantivertigo agent
Mechanism of action
Has antihistaminic activity and inhibits calcium-ion transport across cell membranes. Its calcium-antagonist activity reduces vestibular sensory-cell calcium influx; it also has central vestibular-sedative and antiemetic effects.
Indications / reported uses
  • Control of vestibular disorders such as vertigo, tinnitus, nausea and vomiting associated with Ménière’s disease or other labyrinthine disorders
  • Prevention and control of motion sickness

Sources: UK product SmPC — Cinnarizine 15 mg tablets · NHS medicine information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Cinnarizine Environmental Risk Assessment (ERA) (the Cinnarizine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.